t is well recognized that the renin-angiotensin system (RAS) in the brain controls cardiovascular function by regulating fluid homeostasis and the sympathetic nervous system. Intracerebroventricular administration of angiotensin-II (Ang-II) causes a potent dipsogenic response through its action in forebrain nuclei such as the subfornical organ (SFO) and is mediated by AT1 receptors.
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t is well recognized that the renin-angiotensin system (RAS) in the brain controls cardiovascular function by regulating fluid homeostasis and the sympathetic nervous system. Intracerebroventricular administration of angiotensin-II (Ang-II) causes a potent dipsogenic response through its action in forebrain nuclei such as the subfornical organ (SFO) and is mediated by AT1 receptors. [1] [2] [3] Similarly, AT1 receptor activation causes increased sympathetic activity to the vasculature, heart, and kidney. 4 Activation of the brain RAS has been recently shown to have metabolic effects, and the mechanisms controlling the dipsogenic versus metabolic responses to brain RAS activation are mediated by divergent efferent pathways. 5 Interestingly, brain RAS-elicited metabolic responses are mediated by a complex interplay between central AT1 receptors and adipose tissue AT2 receptors, suggesting a brain/ adipose axis regulated by the brain RAS. 6 Previous studies suggested a physiological link between Ang-II and leptin signaling in the regulation of the sympathetic nervous system, transcribe the renin gene in the brain. Under baseline conditions, transcription of renin mRNA in the brain occurs at an alternative promoter compared with the promoter used to transcribe renin in renal juxtaglomerular cells. 12, 13 The product of this transcript (termed Ren-b) is brain specific, lacks the signal peptide, and is therefore unlikely to be secreted. The predicted translation product of Ren-b lacks the first third of the prosegment and was shown to be enzymatically active. 12 However, it was unclear if Ren-b expression is physiologically significant.
To define a function for Ren-b, we deleted the DNA surrounding and including the Ren-b promoter.
11 Surprisingly, removing the capacity for Ren-b expression resulted in increased expression of Ren-a, encoding preprorenin. This activation of Ren-a occurs concomitantly with increased brain RAS activity and hypertension, suggesting an inhibitory model of renin gene regulation, which suppresses RAS activity in the brain. Supporting this model, there is a switch in expression from primarily Ren-b in the brain of untreated wild type mice to the expression of primarily Ren-a within the brain in response to deoxycorticosterone acetate (DOCA)-salt treatment.
14 This suggests a novel mechanism by which certain physiological cues causes a disinhibition of Ren-a.
It is notable that DOCA-salt hypertension is characterized by increased brain RAS activity because the hypertension can be blocked by brain-specific administration of angiotensin-converting enzyme inhibitors or AT1 receptor blockers. 15, 16 Similarly, the hypertension in Ren-b Null mice can be blocked by renin inhibitors, angiotensin-converting enzyme inhibitors, or AT1 receptor blockers suggesting some similarity between the models.
11 DOCA-salt also increases RMR that is blunted by intracerebroventricular infusion of losartan. 17 Moreover, like the DOCA-salt model, double transgenic sRA mice, which overexpress (1) human angiotensinogen at its normal sites of synthesis, and (2) renin-a selectively in the brain, exhibit severe hypertension, increased fluid intake, and increased RMR. 5, 18 It is notable that the increased Ang-II in sRA mice is brain specific and is because of overexpression of Ren-a, but not Ren-b. Indeed, there was no manipulation of endogenous Ren-b in sRA mice. In this study, we hypothesize that mice carrying a deficiency in Ren-b (Ren-b Null ) mice develop several cardinal phenotypes evoked by increased activity of the brain RAS. We tested the specific hypothesis that Ren-b Null mice exhibit increased fluid intake and RMR.
Methods
Details of the drinking studies, analysis of blood chemistry and urinary steroids, measures and calculations to determine metabolic rate, measures of brown adipose tissue (BAT) sympathetic nerve activity, studies to assess glucose tolerance, insulin sensitivity and glucose uptake, and methods for Western blot and RNA isolation are provided in the online-only Data Supplement.
Renin-b Null Mice
Generation, validation, and initial characterization of Ren-b Null mice was previously reported. 11 Mice carrying the Ren-b Null allele were maintained by backcross breeding to C57BL/6J, and heterozygotes were intercrossed to generate the Ren-b Null mice. Male and female mice were fed standard laboratory chow (NIH-31 modified 6 kcal% mouse diet, Harlan Teklad) and tap water ad libitum. For high-fat diet (HFD) studies, mice were fed D12451 (45 kcal% fat, Research Diets) for 16 weeks beginning at 6 weeks of age. All studies were approved by the University of Iowa Animal Care and Use Committee and were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Statistics
Data were analyzed using t tests or 1-or 2-way analysis of variance with repeated measures as appropriate, followed by Tukey multiple comparisons procedures. Analysis of variance results are presented in each figure legend. Analysis of covariance was used to analyze RMR data using SPSS. All data are presented as mean±SEM. Differences were considered significant if P<0.05. Where appropriate individual data points are plotted in dot/whisker plots and individual statistical tests are noted in the figure legend.
Results
We first measured fluid intake in a cohort of Ren-b Null and control mice using a 2-bottle choice paradigm where mice were given a choice of either tap water or 0.15 mol/L saline. There was no significant change in baseline fluid intake or saline preference in Ren-b
Null mice (Table S1 in online-only Data Supplement). Similarly, there were no changes in urine volume, urinary sodium excretion, or potassium excretion in Ren-b
Null mice nor changes in urinary corticosterone or aldosterone. Because the level of brain RAS activity in Ren-b Null mice is likely to be lower than in sRA mice, which exhibit brain-selective Ang-II overexpression, we asked if a further stimulus was required to unmask an augmented response in Ren-b Null mice. DOCA-salt, which activates the brain RAS, 17 caused an increase in the fluid intake in both groups of mice, but did not cause an exaggerated increase in fluid intake in Ren-b Null mice (Table S1 ). As expected, urine volume and urinary sodium excretion increased in both Ren-b Null and control mice after DOCA-salt. Next, we tested the drinking responses to a dehydration stimulus by measuring water intake after mice were deprived of fluids for 18 hours. Water consumption increased at a similar rate at first, but began to diverge by 30 minutes ( Figure 1A ). After 2 hours, there was a trend for increased water consumption after dehydration in Ren-b Null mice but this difference did not reach significance ( Figure 1B ). On the contrary, DOCA-salt treated Ren-b
Null mice subjected to dehydration exhibited augmented water intake compared with DOCA-salt treated control mice also subjected to dehydration. These data suggest that activation of brain RAS activity caused by Ren-b deficiency may be insufficient on its own to stimulate water intake, whereas dehydration provides a stimulus or behavioral sensitization which augments the dipsogenic response in the model.
To assess if there are alterations in metabolic responses in Ren-b
Null mice, we recorded body weight from 6 to 22 weeks of age. There was no difference in body weight or fat mass in either male ( (Table S2 ). In males, there was a blunting of the increased inguinal WAT mass depot in Ren-b Null mice. Interestingly, HFD caused a marked increase in the size of the liver in control mice that was blunted in male Ren-b
Null (Table  S2 ). The change in liver size only occurred in males.
Body weight in female Ren-b
Null and control mice fed HFD appeared to increase at a similar rate until about 18 weeks of age when they started to diverge ( Figure 2D ). The rate of weight gain in response to HFD was less in female mice than in male mice. At 22 weeks of age, HFD caused an increase in body weight and fat mass in control mice that was blunted in female Ren-b Null mice ( Figure 2E and 2F). Like males, female Ren-b
Null and control mice exhibited increased interscapular BAT, perigenital WAT, and inguinal WAT mass in response to HFD (Table S2 ). However, unlike males, there was a blunted increase in perigenital WAT in female Ren-b
Null mice.
The difference in body weight was not because of differences in food consumption ( Figure 3A) , energy absorption ( Figure 3B ), or physical activity ( Figure 3C ) between male Ren-b
Null and control mice. We next measured RMR by respirometry plotting kcal/h of O 2 versus body weight in a cohort of 46 Ren-b
Null and 53 control male and female mice fed either chow or HFD ( Figure 3D ). Regression analysis revealed an increase in RMR in Ren-b Null mice that was confirmed when Analysis of covariance-adjusted RMR was considered ( Figure 3E ). Given the increase in RMR, we asked if there was increased expression of UCP1 (uncoupling Null mice fed either chow or HFD. There was no increase in UCP1 in perigenital WAT (data not shown). Consistent with the increase in RMR and UCP1 in BAT, sympathetic nerve activity to the BAT was elevated in Ren-b Null mice fed chow ( Figure 4C and 4D ). Because RAS modulators have consistently beneficial effects on glycemic control in humans, 19 we examined if under chow conditions, there were changes in glucose tolerance and insulin sensitivity in Ren-b Null mice. When injected at 1 g/kg, there was no evidence for glucose intolerance in Ren-b Null mice ( Figure 5A ). However, this was modestly worsened when glucose was injected at 2 g/kg ( Figure 5B), such that the area under the curve was significantly increased ( Figure 5C ). There was a modest increase in insulin sensitivity when insulin was injected at 1 U/kg, but not at 0.5 U/kg ( Figure 5D and 5E ), but the decrease in the area under the curve did not reach significance ( Figure 5F ; P=0.08). No differences in plasma insulin levels were observed in fasting or ad libitum-fed Ren-b Null mice (data not shown). Given the trend for increased insulin sensitivity, we repeated the glucose and insulin tolerance tests in sRA mice which exhibit a much greater increase in brain RAS activity. Although there was only a modest improvement in glucose tolerance ( Figure 6A ), sRA mice exhibited profound sensitivity to insulin ( Figure 6B) . Note that only a low dose of insulin was tested because several sRA mice became distressed and the experiment had to be terminated before completion. Differences in area under the curve comparing sRA and control mice was significant (P=0.017). Consistent with increased insulin sensitivity, sRA mice exhibited an increase in glucose uptake in BAT ( Figure 6C ).
Discussion
There are several main findings of the current study. First, whereas Ren-b Null mice do not exhibit changes in fluid intake or salt preference under baseline conditions or after DOCAsalt, 18 hours of dehydration caused increased water intake in Ren-b Null mice. Second, Ren-b Null mice exhibit resistance to diet-induced obesity particularly in males. Third, the resistance to HFD-induced weight gain was not because of changes in food intake, energy absorption, or physical activity, but seems to be because of increased energy expenditure as indicated by the elevated RMR, increased UCP1 mRNA and protein in BAT, and increased BAT sympathetic nerve activity. Fourth, there were only modest changes in glucose tolerance and insulin sensitivity in Ren-b Null mice. sRA mice exhibit much higher brain RAS activity because of marked overexpression of human Ren-a (but not Ren-b) and human AGT in the brain, and exhibit larger increases in blood pressure, drinking, and metabolic phenotypes than Ren-b Null mice. sRA mice were particularly insulin sensitive. 5, 18 Increased activity of the brain RAS has been implicated in many models of hypertension and this is most often associated with increased activity of the sympathetic nervous system. 10 Increased sympathetic outflow in humans has been attributed to be the basis of the failure of antihypertensive therapy in some forms of resistant hypertension such as refractory hypertension. 20 Whether refractory hypertension or neurogenic hypertension in humans is because of increased activity of the brain RAS remains an unanswered question. Interestingly, we previously showed that the same brain-specific isoform of renin mRNA (Ren-b) expressed in the brain of mice and rats is also selectively expressed in the human brain suggesting its function may be conserved. 13 We originally developed the hypothesis that Ren-b encodes an intracellular renin, which may play a role in the generation of intracellular Ang-II. Conceptually, this hypothesis, if supported experimentally, could have provided the missing link defining Ang-II as a neurotransmitter. 21 Indeed, Ang-II satisfies many of the requirements as a neurotransmitter, except the mechanism for its intracellular synthesis and sorting to the neurosecretory system was lacking. 22 But instead of hypotension and resistance to high blood pressure, Ren-b Null mice displayed hypertension.
11
Moreover, the increased arterial pressure was accompanied by increased activity of the brain RAS, as evidenced by increased expression of Ren-a and AT1 receptor mRNAs in some regions of the brain, and a robust depressor response to intracerebroventricular administration of either a renin inhibitor, angiotensin-converting enzyme inhibitor, or AT1 receptor blocker. Our data certainly do not experimentally rule out Ang-II as a neurotransmitter, but did not provide additional support for intracellular synthesis through intracellular renin. Thus, this necessitated a reevaluation of the original concept. The findings that (1) expression of Ren-a, which is dormant in brain of normal mice, was increased in Ren-b Null mice, and (2) Ren-a expression is increased and Ren-b expression is decreased in DOCA-salt hypertension suggested the possibility that this may occur naturally and play a regulatory role.
14 Based on a preponderance of the evidence, we hypothesize that (1) there is a tight selective transcriptional regulation of Ren-b and Ren-a, and (2) disinhibition of Ren-a may occur in response to physiological or pathophysiological cues. However, the molecular mechanism whereby Ren-a disinhibition occurs remains unclear. We have reviewed possible mechanisms by which this transcriptional regulatory circuit could be operating. 10 In the current study, Ren-b Null mice exhibited normal intake of fluids under baseline and DOCA-salt conditions. It was not until the mice were provided a more potent stimulus, dehydration, before an increase in water intake was observed, and then primarily after DOCA-salt. Numerous studies, most recently optogenetics have implicated the SFO as an important regulator of fluid intake. 23, 24 Water deprivation increases neural activity in the SFO, along with other structures in the lamina terminalis. 25 We previously showed that increased synthesis of Ang-II specifically in the SFO is sufficient to induce water intake. 26, 27 There was no increase in total renin mRNA in the SFO of Ren-b Null mice. 11 However, that there was maintenance of total renin mRNA expression in the SFO of Ren-b
Null mice implies there must have been a redistribution of renin mRNA isoforms from Ren-b to Ren-a. One possible interpretation of this is that Ren-b deficiency would provide an opportunity to increase the secretion of prorenin in the SFO which, perhaps in the presence of prorenin receptor, may cause local Ang-II synthesis. 28 Inconsistent with this interpretation was that Renb Null mice did not exhibit increased water intake at baseline suggesting either that the level of Ang-II produced in Renb
Null mice is insufficient to increase drinking or the increase occurred in regions of the brain unrelated to fluid homeostasis. Compared with fluid intake, much more dramatic effects were observed on body weight, particularly when mice were fed HFD. Although there were no differences in body weight in male or female Ren-b Null mice fed a chow diet, male mice in particular exhibited a blunted increase in weight gain in response to HFD. Ren-b
Null mice also exhibited an increase in RMR. We evaluated both male and female mice fed either chow or HFD and used analysis of covariance to examine the relationship between RMR, measured by respirometry, over a wide range of body weights. Factors which influence measurements of RMR have been recently reviewed. 29 Consistent with the increase in RMR, BAT UCP-1 mRNA and protein as well as sympathetic nerve activity (SNA) were significantly elevated in Ren-b Null mice. Together, these observations imply an increase in thermogenesis in Ren-b
Null mice most likely initiated by increased sympathoexcitation to the BAT. Our data also imply increased Ang-II in a neural circuit controlling energy balance, and consistent with this, AT1 receptor expression was increased in the paraventricular nucleus of Ren-b Null . 11 The paraventricular nucleus is a major integrating center for both cardiovascular and metabolic responses and AT1 receptors have been localized in the paraventricular nucleus. 30, 31 As above, there was no increase in total renin mRNA in the arcuate nucleus, but again, the redistribution of Ren-a/Ren-b may provide a source of extracellular prorenin/renin needed for local Ang-II synthesis in this nucleus.
This may be significant as AT1 receptor mRNA are localized on some leptin receptor containing neurons in the arcuate nucleus which regulate RMR. 8 Deletion of AT1 receptor in mice or inhibition of angiotensin production and action in the brain of rats blunts sympathetic activity to the kidney and BAT in response to centrally administered leptin. 7 Thus, it would be interesting to assess if renin-mediated production of Ang-II in the arcuate nucleus is required to mediate SNA to thermogenic BAT.
One of the curious observations was that UCP1 and increased BAT SNA was observed in chow-fed mice, but body weight was similar in chow-fed control and Ren-b Null mice. This could indicate that the increase in UCP1 expression is insufficient to affect adiposity and body weight at least when mice are fed a chow diet. However, we found that challenging mice with HFD revealed a difference in adiposity and body weight. Whether the decrease in weight gain and adiposity is mechanistically related to the increase in RMR remains unclear.
Perspectives
Disruption of Ren-b caused a modest but statistically significant reduction in glucose tolerance, and simultaneously caused a trend toward increased insulin sensitivity. In parallel, transgenic activation of the brain RAS in sRA mice resulted in a more robust increase in insulin sensitivity, as quantified by positron emission tomography/computed tomography imaging, presumably because of increased BAT SNA. These results complement our previous observation of increased glucose uptake in thermogenic adipose of sRA mice, assessed using radiolabeled glucose uptake quantification. 6 Along these lines, it is interesting to note that RAS blockade has been reported to prevent insulin resistance. [32] [33] [34] Similarly, in clinical trials, RAS blockade is more effective than other antihypertensives which do not target the RAS at improving insulin sensitivity. 35, 36 Other large clinical trials suggest benefit from RAS blockade on incidence of diabetes mellitus or glucose tolerance, or both. 19, 33, 37 At first, our results in Ren-b Null and sRA with increased brain RAS activity seem in contradiction to the clinical benefits of RAS inhibition. However, Ren-b Null and sRA are both characterized by a decrease in systemic RAS activity (because of feedback inhibition caused by hypertension). 5, 11 We previously demonstrated that the coupling of reduced systemic (or circulating) RAS activity with increased sympathetic nerve activity to adipose tissue stimulates thermogenesis and RMR. 6 Further studies are clearly needed to assess if these observations can be translated therapeutically. 
